Have a personal or library account? Click to login
Unraveling MINOCA: The hidden impact of inflammation on myocardial infarction without coronary obstruction Cover

Unraveling MINOCA: The hidden impact of inflammation on myocardial infarction without coronary obstruction

Open Access
|Sep 2025

References

  1. Pasupathy S, Air T, Dreyer RP, Tavella R, Beltrame JF. Systematic Review of Patients Presenting With Suspected Myocardial Infarction and Nonobstructive Coronary Arteries. Circulation. 2015;131(10): 861-70.
  2. Agewall S, Beltrame JF, Reynolds HR, Niessner A, Rosano G, Caforio ALP, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. European Heart Journal. 2016;38(3): 143-53.
  3. Matter MA, Paneni F, Libby P, Frantz S, Stähli BE, Templin C, et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. European Heart Journal. 2023;45(2): 89-103.
  4. Klingenberg R, Luscher TF. Inflammation in coronary artery disease and acute myocardial infarction - is the stage set for novel therapies? Curr Pharm Des. 2012;18(28): 4358-69.
  5. Hjort M, Eggers KM, Lindhagen L, Agewall S, Brolin EB, Collste O, et al. Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries. Clin Chem. 2019;65(8): 1023-30.
  6. Monteiro E, Barbosa J, Guimaraes J, Fernandes D, Costa G, Gomes R, et al. Prognostic impact of inflammation in myocardial infarction with non-obstructive coronary arteries. European Heart Journal. 2023;44(Supplement_2).
  7. Gaibazzi N, Martini C, Botti A, Pinazzi A, Bottazzi B, Palumbo AA. Coronary Inflammation by Computed Tomography Pericoronary Fat Attenuation in MINOCA and Tako-Tsubo Syndrome. J Am Heart Assoc. 2019;8(17): e013235.
  8. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12): 1119-31.
  9. Gan J, Guo L, Zhang X, Yu Q, Yang Q, Zhang Y, et al. Anti-inflammatory therapy of atherosclerosis: focusing on IKKβ. Journal of Inflammation. 2023;20(1): 8.
  10. Maguire EM, Pearce SWA, Xiao Q. Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease. Vascul Pharmacol. 2019;112:54-71.
  11. Melamed KH, Goldhaber SZ. Inflammation and Myocardial Infarction. Circulation. 2014;130(24): e334-e6.
  12. Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, et al. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther. 2022;7(1): 78.
  13. Zheng Y, Xu L, Dong N, Li F. NLRP3 inflammasome: The rising star in cardiovascular diseases. Front Cardiovasc Med. 2022;9: 927061.
  14. Balanescu S, Barbu E, Georgescu C, Popescu AC. NLRP3 Inflammasome in Cardiovascular Disease: David’s Stone against Goliath? Romanian Journal of Cardiology. 2021;31(3): 517-27.
  15. Takahashi M. Role of NLRP3 Inflammasome in Cardiac Inflammation and Remodeling after Myocardial Infarction. Biol Pharm Bull. 2019;42(4): 518-23.
  16. Coste MER, França CN, Izar MC, Teixeira D, Ishimura ME, Longo-Maugeri I, et al. Early Changes in Circulating Interleukins and Residual Inflammatory Risk After Acute Myocardial Infarction. Arq Bras Cardiol. 2020;115(6): 1104-11.
  17. Barbu E, Popescu MR, Popescu AC, Balanescu SM. Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging. Int J Mol Sci. 2022;23(2).
  18. Silvis MJM, Demkes EJ, Fiolet ATL, Dekker M, Bosch L, van Hout GPJ, et al. Immunomodulation of the NLRP3 Inflammasome in Atherosclerosis, Coronary Artery Disease, and Acute Myocardial Infarction. Journal of Cardiovascular Translational Research. 2021;14(1): 23-34.
  19. Toldo S, Mezzaroma E, Buckley LF, Potere N, Di Nisio M, Biondi-Zoccai G, et al. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacol Ther. 2022;236: 108053.
  20. Louwe MC, Olsen MB, Kaasbøll OJ, Yang K, Fosshaug LE, Alfsnes K, et al. Absence of NLRP3 Inflammasome in Hematopoietic Cells Reduces Adverse Remodeling After Experimental Myocardial Infarction. JACC: Basic to Translational Science. 2020;5(12): 1210-24.
  21. Berg DD, O’Donoghue ML, Jarolim P, Guo J, Sabatine MS, Morrow DA. Biomarkers in the IL-6 Pathway and Cardiovascular Outcomes in Patients With STEMI in LATITUDE-TIMI 60. JACC Adv. 2024;3(4): 100866.
  22. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013;168(6):5126-34.
  23. Oikonomou EK, Marwan M, Desai MY, Mancio J, Alashi A, Hutt Centeno E, et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet. 2018;392(10151): 929-39.
  24. Araki M, Sugiyama T, Nakajima A, Yonetsu T, Seegers LM, Dey D, et al. Level of Vascular Inflammation Is Higher in Acute Coronary Syndromes Compared with Chronic Coronary Disease. Circulation: Cardiovascular Imaging. 2022;15(11): e014191.
  25. Sagris M, Antonopoulos AS, Simantiris S, Oikonomou E, Siasos G, Tsioufis K, et al. Pericoronary fat attenuation index-a new imaging biomarker and its diagnostic and prognostic utility: a systematic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2022;23(12): e526-e36.
  26. Kain V, Prabhu SD, Halade GV. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Research in Cardiology. 2014;109(6): 444.
  27. Haim M, Tanne D, Boyko V, Reshef T, Goldbourt U, Battler A, et al. Monocyte chemoattractant protein-1 and recurrent cardiovascular events in patients with stable coronary heart disease. Clinical Cardiology. 2005;28(1): 31-5.
  28. Shantsila E, Lip GYH. Monocytes in Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29(10): 1433-8.
  29. Klingenberg R, Nitschmann S. [Colchicine treatment after myocardial infarction : Colchicine Cardiovascular Outcomes Trial (COLCOT)]. Internist (Berl). 2020;61(7): 766-9.
  30. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383(19): 1838-47.
  31. Abbate A, Wohlford GF, Del Buono MG, Chiabrando JG, Markley R, Turlington J, et al. Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother. 2022;8(5): 503-10.
  32. Del Buono MG, Damonte JI, Trankle CR, Kadariya D, Carbone S, Thomas G, et al. Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction. Scientific Reports. 2022;12(1): 1254.
  33. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359(21): 2195-207.
  34. Gao R, Shi H, Chang S, Gao Y, Li X, Lv C, et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. Int Immunopharmacol. 2019;74: 105575.
  35. Bromage DI, Pareek N, Cannata A, Ameri P. Targeting Inflammation After Myocardial Infarction—Another Piece of the Puzzle. Journal of Cardiovascular Pharmacology. 2022;79(6): 769-71.
  36. Yildiz M, Ashokprabhu N, Shewale A, Pico M, Henry TD, Quesada O. Myocardial infarction with non-obstructive coronary arteries (MINOCA). Frontiers in Cardiovascular Medicine. 2022;9.
  37. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjöld A, Gard A, et al. Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. Circulation. 2017;135(16): 1481-9.
  38. Yaker ZS, Lincoff AM, Cho L, Ellis SG, Ziada KM, Zieminski JJ, et al. Coronary spasm and vasomotor dysfunction as a cause of MINOCA. EuroIntervention. 2024;20(2): e123-e34.
  39. Nobuyoshi M, Abe M, Nosaka H, Kimura T, Yokoi H, Hamasaki N, et al. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant. Am Heart J. 1992;124(1): 32-8.
  40. Montone RA, Niccoli G, Fracassi F, Russo M, Gurgoglione F, Cammà G, et al. Patients with acute myocardial infarction and non-obstructive coronary arteries: safety and prognostic relevance of invasive coronary provocative tests. European Heart Journal. 2017;39(2): 91-8.
  41. Hung MJ, Cherng WJ. Coronary Vasospastic Angina: Current Understanding and the Role of Inflammation. Acta Cardiol Sin. 2013;29(1): 1-10.
  42. Tamis-Holland JE, Jneid H, Reynolds HR, Agewall S, Brilakis ES, Brown TM, et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139(18): e891-e908.
  43. Reynolds HR, Maehara A, Kwong RY, Sedlak T, Saw J, Smilowitz NR, et al. Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women. Circulation. 2021;143(7): 624-40.
  44. Shibata T, Kawakami S, Noguchi T, Tanaka T, Asaumi Y, Kanaya T, et al. Prevalence, Clinical Features, and Prognosis of Acute Myocardial Infarction Attributable to Coronary Artery Embolism. Circulation. 2015;132(4): 241-50.
  45. Opolski MP, Spiewak M, Marczak M, Debski A, Knaapen P, Schumacher SP, et al. Mechanisms of Myocardial Infarction in Patients With Nonobstructive Coronary Artery Disease: Results From the Optical Coherence Tomography Study. JACC: Cardiovascular Imaging. 2019;12(11, Part 1): 2210-21.
  46. Stepien K, Nowak K, Wypasek E, Zalewski J, Undas A. High prevalence of inherited thrombophilia and antiphospholipid syndrome in myocardial infarction with non-obstructive coronary arteries: Comparison with cryptogenic stroke. Int J Cardiol. 2019;290: 1-6.
  47. Safdar B, Spatz ES, Dreyer RP, Beltrame JF, Lichtman JH, Spertus JA, et al. Presentation, Clinical Profile, and Prognosis of Young Patients With Myocardial Infarction With Nonobstructive Coronary Arteries (MINOCA): Results From the VIRGO Study. J Am Heart Assoc. 2018;7(13).
  48. Ouldzein H, Elbaz M, Roncalli J, Cagnac R, Carrié D, Puel J, et al. Plaque rupture and morphological characteristics of the culprit lesion in acute coronary syndromes without significant angiographic lesion: Analysis by intravascular ultrasound. Annales de Cardiologie et d ‘Angéiologie. 2012;61(1): 20-6.
  49. Sucato V, Testa G, Puglisi S, Evola S, Galassi AR, Novo G. Myocardial infarction with non-obstructive coronary arteries (MINOCA): Intracoronary imaging-based diagnosis and management. Journal of Cardiology. 2021;77(5): 444-51.
  50. Ciliberti G, Finocchiaro G, Guerra F, Papadakis M, Sharma S, Sheppard M. Different clinical and pathological profiles of sudden cardiac death victims caused by coronary artery dissection or myocardial infarction with non-obstructed coronary arteries. European Heart Journal. 2022;43(Supplement_2).
  51. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, et al. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2018;137(19): e523-e57.
  52. Tweet MS, Eleid MF, Best PJM, Lennon RJ, Lerman A, Rihal CS, et al. Spontaneous Coronary Artery Dissection. Circulation: Cardiovascular Interventions. 2014;7(6):777-86.
  53. Espinosa Pascual MJ, Martin Munoz M, El Assar De La Fuente M, Nieto Ibanez D, Camara Hernandez V, Carnicero Carreno J, et al. Increased circulating levels of standardized inflammatory and endothelial dysfunction biomarkers in patients with myocardial infarction with nonobstructive coronary arteries. European Heart Journal. 2024;45(Supplement_1).
  54. Fanola CL, Morrow DA, Cannon CP, Jarolim P, Lukas MA, Bode C, et al. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial. Journal of the American Heart Association. 2017;6(10): e005637.
  55. Ryabov VV, Vorobeva DA, Kologrivova IV, Suslova TE. Pro-Inflammatory Biomarkers and Progression of Atherosclerosis in Patients with Myocardial Infarction with Non-Obstructive Coronary Artery Disease: 1-Year Follow-Up. J Pers Med. 2023;13(12).
  56. Ciliberti G, Bergamaschi L, Armillotta M, Angeli F, Pizzi C. MINOCA and inflammation: Another piece of the puzzle. International Journal of Cardiology. 2025;419.
  57. Haybar H, Bandar B, Torfi E, Mohebbi A, Saki N. Cytokines and their role in cardiovascular diseases. Cytokine. 2023;169: 156261.
  58. Stangret A, Dykacz W, Jabłoński K, Wesołowska A, Klimczak-Tomaniak D, Kochman J, et al. The cytokine trio - visfatin, placental growth factor and fractalkine – and their role in myocardial infarction with non-obstructive coronary arteries (MINOCA). Cytokine & Growth Factor Reviews. 2023;74: 76-85.
  59. Espinosa Pascual MJ, Lopez Pais J, Izquierdo Coronel B, Nieto Ibanez D, Galan Gil D, Perela Alvarez C, et al. Role of inflammation in Myocardial Infarction with Non-Obstructive Coronary Arteries. European Heart Journal. 2021;42(Supplement_1).
  60. Pasqualetto MC, Tuttolomondo D, Cutruzzolà A, Niccoli G, Dey D, Greco A, et al. Human coronary inflammation by computed tomography: Relationship with coronary microvascular dysfunction. Int J Cardiol. 2021;336: 8-13.
  61. Zhang S, Zhang X, Wu S, Zhang T, Ji HM, Zhang Q, et al. [Analysis of clinical features and the outcome of in-hospital mortality of myocardial infarction with non-obstructive coronary arteries]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022;50(9): 873-80.
  62. Pelliccia F, Pasceri V, Niccoli G, Tanzilli G, Speciale G, Gaudio C, et al. Predictors of Mortality in Myocardial Infarction and Nonobstructed Coronary Arteries: A Systematic Review and Meta-Regression. The American Journal of Medicine. 2020;133(1): 73-83.e4.
  63. Nordenskjöld AM, Baron T, Eggers KM, Jernberg T, Lindahl B. Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease. Int J Cardiol. 2018;261: 18-23.
  64. Canton L, Fedele D, Bergamaschi L, Foà A, Di Iuorio O, Tattilo FP, et al. Sex- and age-related differences in outcomes of patients with acute myocardial infarction: MINOCA vs. MIOCA. European Heart Journal Acute Cardiovascular Care. 2023;12(9): 604-14.
  65. Chaudhary R, Bashline M, Novelli EM, Bliden KP, Tantry US, Olafiranye O, et al. Sex-related differences in clinical outcomes among patients with myocardial infarction with nonobstructive coronary artery disease: A systematic review and meta-analysis. International Journal of Cardiology. 2022;369: 1-4.
  66. Tsaban G, Barret O, Peles I, Abramowitz Y, Shmueli H, Cafri C, et al. Prognostic factors of patients with myocardial infarction with nonobstructive coronary artery disease: a seven-year longitudinal follow-up. European Heart Journal. 2022;43(Supplement_2).
  67. Chen L, Fan Y, Fang Z, Liu N. Long-term outcomes and predictors of patients with ST elevated versus non-ST elevated myocardial infarctions in non-obstructive coronary arteries: a retrospective study in Northern China. PeerJ. 2023;11: e14958.
  68. Gao S, Xu H, Ma W, Yuan J, Yu M. Remnant Cholesterol Predicts Risk of Cardiovascular Events in Patients With Myocardial Infarction With Nonobstructive Coronary Arteries. Journal of the American Heart Association. 2022;11(10): e024366.
  69. Gao S, Ma W, Huang S, Lin X, Yu M. Effect of Lipoprotein (a) Levels on Long-term Cardiovascular Outcomes in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries. The American Journal of Cardiology. 2021;152: 34-42.
  70. Kallmeyer A, Pello Lázaro AM, Blanco-Colio LM, Aceña Á, González-Lorenzo Ó, Tarín N, et al. Absence of High Lipoprotein(a) Levels Is an Independent Predictor of Acute Myocardial Infarction without Coronary Lesions. Journal of Clinical Medicine. 2023;12(3): 960.
  71. Kong M, Pei Z, Xie Y, Gao Y, Li J, He G. Prognostic factors of MINOCA and their possible mechanisms. Preventive Medicine Reports. 2024;39: 102643.
  72. Hjort M, Eggers KM, Lakic TG, Lindbäck J, Budaj A, Cornel JH, et al. Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial. Journal of the American Heart Association. 2023;12(1): e027466.
  73. Eggers KM, Baron T, Hjort M, Nordenskjöld AM, Tornvall P, Lindahl B. Clinical and prognostic implications of C-reactive protein levels in myocardial infarction with nonobstructive coronary arteries. Clin Cardiol. 2021;44(7): 1019-27.
  74. Fang Y, Huang S, Zhang H, Yu M. The association between fibrinogen-to-albumin ratio and adverse prognosis in patients with myocardial infarction with non-obstructive coronary arteries. Int J Cardiol. 2025;418: 132665.
  75. Zhou H, Li X, Wang W, Zha Y, Gao G, Li S, et al. Immune-inflammatory biomarkers for the occurrence of MACE in patients with myocardial infarction with non-obstructive coronary arteries. Frontiers in Cardiovascular Medicine. 2024;11.
  76. Hou H, Xu Y, Chen G, Yao H, Bi F. Prognostic Value of Systemic Inflammation Response Index and N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries-A Retrospective Study. J Inflamm Res. 2024;17: 8281-98.
  77. Gürdal A, Keskin K, Siğirci S, Yildiz SS, Kiliçkesmez KO. Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries. Angiology. 2020;71(9): 812-6.
  78. Mohammed AA, Liu L, Mareai RM, Mohammed AQ, Yin G, Singh S, et al. Combination of White Blood Cell Count to Mean Platelet Volume Ratio and Neutrophil-to-Platelet Ratio Predicts Long-Term Adverse Events in Patients with MINOCA. Mediators Inflamm. 2022;2022: 5642406.
  79. Ma W, Gao S, Huang S, Yuan J, Yu M. Hyperuricemia as a prognostic marker for long-term outcomes in patients with myocardial infarction with nonobstructive coronary arteries. Nutrition & Metabolism. 2021;18(1): 107.
  80. Al-Badri A, Tahhan AS, Sabbak N, Alkhoder A, Liu C, Ko YA, et al. Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease. Journal of the American Heart Association. 2020;9(8): e015515.
  81. Bergamaschi L, Foà A, Paolisso P, Renzulli M, Angeli F, Fabrizio M, et al. Prognostic Role of Early Cardiac Magnetic Resonance in Myocardial Infarction With Nonobstructive Coronary Arteries. JACC: Cardiovascular Imaging. 2024;17(2):149-61.
  82. Zeng M, Zhao C, Bao X, Liu M, He L, Xu Y, et al. Clinical Characteristics and Prognosis of MINOCA Caused by Atherosclerotic and Nonatherosclerotic Mechanisms Assessed by OCT. JACC: Cardiovascular Imaging. 2023;16(4): 521-32.
DOI: https://doi.org/10.2478/rjc-2025-0016 | Journal eISSN: 2734-6382 | Journal ISSN: 1220-658X
Language: English
Page range: 175 - 187
Published on: Sep 30, 2025
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Andra Ioana Stoenescu, Elena Barbu, Serban-Mihai Balanescu, published by Romanian Society of Cardiology
This work is licensed under the Creative Commons Attribution 4.0 License.